SecBot SecBot
144 ·Filed Nov 6, 2026

MDGL

MADRIGAL PHARMACEUTICALS, INC.
NEUTRAL
Impact 2/10
Horizondays Processed10d 8h ago SEC0001950047-26-010779
Form 144: notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine insider sale of vested RSU shares, small in size relative to market cap. No material signal for the stock. Monitor for any pattern of larger insider sales in future filings.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$432.79
T+0 close · Nov 6, 2026 · via day close
Latest settled
−2.04%
T+5 · $423.96
Vs SPY
−0.35%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $432.79entry
  2. T+1 · 7d ago −0.04%α +0.32% · $432.60
  3. T+5 · 18h ago −2.04%α −0.35% · $423.96
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Shannon Kelley, an officer of Madrigal Pharmaceuticals, filed a Form 144 notice of intent to sell 1,077 shares of common stock, with an approximate market value of $430,908 based on a filing date price. The shares were acquired upon vesting of restricted stock units during 2026. The sale represents a small fraction of the company's $9.3B market cap and is a routine insider transaction.

Key Facts

  • Shannon Kelley (officer) filed Form 144 on 2026-11-06 to sell 1,077 shares of MDGL common stock.
  • Estimated sale value: $430,907.70 based on filing date.
  • Shares were acquired upon vesting of restricted stock units between 3/5/2026 and 8/15/2026.
  • Total shares outstanding implied by market cap ($9.3B) and stock price: approximately 21.6 million shares; 1,077 shares represent ~0.005% of shares outstanding.
  • The sale is a routine disposition of vested equity compensation, not a discretionary open-market sale of accumulated holdings.

Financial Impact

Sale of 1,077 shares valued at ~$430,908, representing ~0.005% of market cap.

dilution

Risk Factors

  • Form 144 is an intent to sell; the actual sale may not occur.
  • No information on Kelley's remaining holdings; the filing does not disclose total beneficial ownership.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-010779
Document: 0001950047-26-010779-index.html0001950047-26-010779
Document: 0001950047-26-010779.txt0001950047-26-010779

Track record

18 reports on MDGL

Performance horizon

3 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +10.26% at T+20 after the Jul 30, 2026 report. 3 of 6 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $424.08 Now $423.96 −0.03% settles Nov 23
  2. Nov 6, 202610d ago SC 13D/A Neutral 3/10 Entry $432.79 to $423.96 Now $423.96 −2.04% ▼ −2.04% −0.35% vs SPY
  3. Nov 6, 202610d ago Insider Buy Bullish 5/10 Entry $432.79 to $423.96 Now $423.96 −2.04% ▼ −2.04% −0.35% vs SPY
  4. Nov 6, 202610d ago Insider Cluster Bullish 5/10 Entry $432.79 to $423.96 Now $423.96 −2.04% ▼ −2.04% −0.35% vs SPY
  5. Nov 6, 202610d ago 144 Neutral 2/10 Viewing Entry $432.79 to $423.96 Now $423.96 −2.04% ▼ −2.04% −0.35% vs SPY
  6. Nov 5, 202611d ago Institutional Cluster Mixed 3/10 Entry $400.10 to $425.21 Now $423.96 +5.96% ▲ +6.28% +2.99% vs SPY
  7. Nov 5, 202611d ago Press Release Bullish 5/10 Entry $400.10 to $425.21 Now $423.96 +5.96% ▲ +6.28% +2.99% vs SPY
  8. Nov 3, 202613d ago 8-K Bullish 7/10 No price data
  9. Nov 3, 202613d ago Press Release Bullish 6/10 Entry $396.32 to $432.60 Now $423.96 +6.97% ▲ +9.15% +9.74% vs SPY
  10. Aug 12, 202613w ago 8-K Neutral 3/10 Entry $536.20 to $540.16 Now $423.96 −20.93% ▲ +0.74% +1.18% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens in 8h 58m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 6, 2026